220 related articles for article (PubMed ID: 27875488)
21. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
[TBL] [Abstract][Full Text] [Related]
22. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
[TBL] [Abstract][Full Text] [Related]
23. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
24. Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation.
Röhss K; Wilder-Smith C; Bokelund-Singh S; Sagar M; Nagy P
Dig Dis Sci; 2010 Dec; 55(12):3423-9. PubMed ID: 20238247
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
26. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26422093
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
28. Intravenous esomeprazole.
Keating GM; Figgitt DP
Drugs; 2004; 64(8):875-82; discussion 883. PubMed ID: 15059043
[TBL] [Abstract][Full Text] [Related]
29. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26121345
[TBL] [Abstract][Full Text] [Related]
30. High-dose esomeprazole for treatment of symptomatic refractory gastroesophageal reflux disease--a prospective pH-metry/impedance-controlled study.
Bajbouj M; Becker V; Phillip V; Wilhelm D; Schmid RM; Meining A
Digestion; 2009; 80(2):112-8. PubMed ID: 19641320
[TBL] [Abstract][Full Text] [Related]
31. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
Szucs T; Thalmann C; Michetti P; Beglinger C
Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic Response to 20 mg of Esomeprazole Twice Daily in Patients with Gastroesophageal Reflux Disease-related Non-cardiac Chest Pain: An Open-Label Randomized Pilot Study].
Choi JK; Shim HI; Shin CM; Yoon H; Park YS; Kim N; Lee DH
Korean J Gastroenterol; 2020 Jun; 75(6):333-340. PubMed ID: 32581204
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
Wang H; Shao F; Liu X; Xu W; Ou N; Qin X; Liu F; Hou X; Hu H; Jiang J
Br J Clin Pharmacol; 2019 Nov; 85(11):2547-2558. PubMed ID: 31332820
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo.
Johnson DA; Le Moigne A; Li J; Pollack C; Nagy P
Clin Drug Investig; 2016 Jul; 36(7):531-8. PubMed ID: 27074935
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
[TBL] [Abstract][Full Text] [Related]
39. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
Kirchheiner J; Glatt S; Fuhr U; Klotz U; Meineke I; Seufferlein T; Brockmöller J
Eur J Clin Pharmacol; 2009 Jan; 65(1):19-31. PubMed ID: 18925391
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
